A preliminary, uncontrolled study shows that IFN plus corticosteroids are associated with better disease outcomes in SARS patients compared to corticosteroid treatment alone (Loutfy et al., 2003). This evidence concerns the gene IFNA1 and severe acute respiratory syndrome.